Apogee Therapeutics to Participate in Upcoming March Conferences
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) announced management will participate in three investor events in early March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and attendance at the UBS Biotech Summit Miami (March 9) and Jefferies Biotech on the Beach Summit (March 10). A live and archived webcast of the March 3 fireside chat will be available on the company’s Investors News & Events page.
Positive
- None.
Negative
- None.
News Market Reaction – APGE
On the day this news was published, APGE gained 1.95%, reflecting a mild positive market reaction. This price movement added approximately $91M to the company's valuation, bringing the market cap to $4.78B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged biotech peers IBRX, TARS, and GLPG moving up, but sector momentum was not classified as a coordinated move for APGE.
Market Pulse Summary
This announcement highlighted Apogee Therapeutics’ participation in several March healthcare and biotech conferences, including a fireside chat on March 3, 2026, at 9:10 a.m. Investors typically watched these events for any new guidance, pipeline updates, or strategic shifts beyond routine presentations. With shares trading at $69.91 ahead of the conferences, subsequent commentary or disclosures during these meetings would have been key for reassessing the company’s risk-reward profile.
AI-generated analysis. Not financial advice.
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026.
A live and archived webcast of the fireside chat at the TD Cowen Conference will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When and where will Apogee Therapeutics (APGE) present at the TD Cowen conference?
Will Apogee Therapeutics (APGE) provide a webcast of the March 3 fireside chat?
Which investor conferences will Apogee Therapeutics (APGE) attend in March 2026?
How can investors watch Apogee Therapeutics (APGE) if they cannot attend TD Cowen on March 3?
Who from Apogee Therapeutics (APGE) is scheduled to attend the UBS and Jefferies biotech summits?
